Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunicIMUX -2.82%32 Cash-to-Debt is 273.54 as of Jun. 2026, which is 192% above its 10-year median of 93.72. GuruFocus rates IMUX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,397 Biotechnology companies, Immunic ranks better than 82.53% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Immunic's cash to debt ratio for the quarter that ended in Jun. 2026 was 273.54.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Immuniccould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Immunic's Cash-to-Debt or its related term are showing as below:
IMUX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 14.67 Med: 93.72 Max: No Debt
Current: 273.54
During the past 13 years, Immunic's highest Cash to Debt Ratio was No Debt. The lowest was 14.67. And the median was 93.72.
IMUX's Cash-to-Debt is ranked better than 82.53% of 1397
companies
in the Biotechnology industry
Industry Median: 6.72
vs IMUX: 273.54
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Immunic Cash-to-Debt Related Terms
Immunic Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Immunic's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Immunic's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunic Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunic's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Immunic's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunic (IMUX) has a Cash-to-Debt of 273.54 as of Jun. 2026. This is 192% above median its historical median of 93.72. Over the past decade, Immunic's Cash-to-Debt has ranged from 14.67 to 10,000.00. According to the industry distribution chart, Immunic ranks #244 out of 1397 companies in the Biotechnology industry, placing it in the top 17.5%.
Is Immunic's Cash-to-Debt too high?
Immunic's current Cash-to-Debt of 273.54 is 192% above median its 10-year median of 93.72. Over the past 10 years, this metric has ranged from a low of 14.67 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. Immunic's value of 273.54 is 3970.5% above this industry median. Based on the distribution chart, Immunic ranks #244 out of 1397 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Immunic's Cash-to-Debt compare to ABOS and ANTX?
According to the Biotechnology industry distribution chart, Immunic ranks #244 out of 1397 companies for Cash-to-Debt. This places Immunic in the top 18% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.72. Immunic's value of 273.54 is 3970.5% above this benchmark. Historically, Immunic's own Cash-to-Debt has ranged from 14.67 to 10,000.00 over the past decade. While the company's 10-year median is 93.72 vs. the industry median of 6.72, Immunic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunic's current Cash-to-Debt of 273.54 is 3970.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunic's current Cash-to-Debt is 273.54, which is 192% above median its own 10-year median of 93.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunic stock overvalued right now?
Immunic (IMUX) has a current Cash-to-Debt of 273.54. The current Cash-to-Debt is 273.54, which is 192% above median its 10-year median of 93.72 and 3970.5% above the Biotechnology industry median of 6.72. Immunic's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Immunic (IMUX), the current Cash-to-Debt is 273.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
32GF Score
Get the complete analysis for IMUX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMUX has been successfully added to your 
